trial

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

NCTId NCT02634320
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 51 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2017-07-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
51 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2015-12
Primary completion
2017-07-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Sanjeev Pathak, MDStudy Director

Sites

18 total
Little Rock, United StatesRogers, United StatesAnaheim, United StatesCulver City, United StatesGarden Grove, United StatesNational City, United StatesOceanside, United StatesOrange, United StatesPanorama City, United StatesAugusta, United StatesChicago, United StatesShreveport, United States

Facts & assertions

4 sourced
Enrollment
51
Phase
PHASE4
Primary Completion Date
2017-07-11
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Sanjeev Pathak, MD
person